Use of an antibacterial envelope in spinal cord stimulation reduces the rate and severity of iatrogenic infections
By Admin | March 06, 2024
Received 14 February 2024, Accepted 24 February 2024, Available online 1 March 2024.
Abstract
Aim
To examine if the use of an antibacterial envelope (TYRX) decreases the rate of postoperative infection in chronic pain patients undergoing treatment with spinal cord stimulation (SCS) involving device implantation.
Method
Single center retrospective cohort study comparing postoperative infections rates in non-TYRX recipients from 2018-2020 with recipients of a TYRX antibacterial envelope from 2020-2021. Infection was registered if a patient received any form of antibiotic treatment after hospital discharge within a follow-up period of 100 days.
Results
A total of 198 patients were included. 100 in the TYRX group and 98 in the non-TYRX group. There were no significant differences between the two groups regarding age, BMI, smoking, diabetes, and use of immunosuppression.
The overall infection rate was 5.6%. The infection rate was 4% in the TYRX group and 7.1% in the non-TYRX group (p=0.6). However, the 4 cases of postoperative infection in the TYRX group could be effectively managed with oral antibiotics alone, whereas 6 out of the 7 patients in the non-TYRX group required intravenous antibiotics. Moreover, device explantation was necessary in...(More)
For more info please read, Use of an antibacterial envelope in spinal cord stimulation reduces the rate and severity of iatrogenic infections, by ScienceDirect
